YD Global Life Science is a Korean biopharmaceutical company with ambitions to become a global leader in new drug development with USD 1 billion in revenues. Its founder & CEO, Jin Woo Lee explains his strategy to reach this goal by licensing-out promising compounds acquired from research institutions, developing an in-house pipeline by leveraging the company’s technology platforms including drug repositioning, AI-mediated drug discovery and clinical development, and growing the business through M&A.
Within this year, we are hoping to list our company on the stock market and license-out our treatment for ophthalmological diseases
